Vaxart (VXRT) Expected to Announce Earnings on Thursday

Key Points

• Vaxart (VXRT) is expected to release its Q2 2025 earnings on August 14th, with analysts predicting an earnings loss of ($0.08) per share.
• The company reported a revenue of $20.88 million last quarter, surpassing expectations of $2.85 million, but it also showed a negative net margin of 122.63%.
• Insider Steven Lo recently acquired 100,000 shares of Vaxart, increasing his ownership, and institutional investors have raised their positions in the company significantly in the first quarter.

Vaxart (NASDAQ:VXRT - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Vaxart (NASDAQ:VXRT - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). Vaxart had a negative net margin of 122.63% and a negative return on equity of 91.89%. The company had revenue of $20.88 million during the quarter, compared to analysts' expectations of $2.85 million. On average, analysts expect Vaxart to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vaxart Price Performance

VXRT stock opened at $0.40 on Thursday. Vaxart has a 52-week low of $0.26 and a 52-week high of $1.07. The company has a 50-day moving average of $0.45 and a two-hundred day moving average of $0.49. The stock has a market capitalization of $91.57 million, a price-to-earnings ratio of -1.48 and a beta of 1.12.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Vaxart to a "hold" rating in a report on Thursday, May 22nd.

Insider Activity at Vaxart

In related news, insider Steven Lo acquired 100,000 shares of the business's stock in a transaction dated Monday, May 19th. The stock was acquired at an average price of $0.49 per share, with a total value of $49,000.00. Following the completion of the transaction, the insider owned 100,000 shares of the company's stock, valued at approximately $49,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 2.90% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in VXRT. Goldman Sachs Group Inc. acquired a new position in shares of Vaxart during the first quarter valued at about $31,000. Invesco Ltd. raised its position in shares of Vaxart by 93.1% during the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock valued at $60,000 after buying an additional 70,568 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its position in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after buying an additional 478,111 shares during the last quarter. Institutional investors and hedge funds own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.